New hope for leukemia patients: targeted therapy aims to wipe out hidden cancer cells

NCT ID NCT03737955

First seen Jan 29, 2026 · Last updated May 05, 2026 · Updated 10 times

Summary

This study tests a targeted drug called gemtuzumab ozogamicin in adults with acute myeloid leukemia who are in remission but still have small amounts of cancer cells (measurable residual disease). The drug works like a smart bomb, attaching to a protein on leukemia cells and delivering chemotherapy directly to them. The goal is to clear these hidden cells and improve long-term outcomes. About 36 participants will receive up to two cycles of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutchinson Cancer Center/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.